Search your stocks

Share

Profile

MANKINDMankind Pharma Ltd.

2646.3(+0.30%)

1W: +1.89%

1M: +0.74%

1Y: +14.12%

Financials

Charts

YoY Net Sales

Operating Margin

EPS Growth

Pros & Cons

POSITIVES

Revenue growth increased by 15% year-on-year, indicating strong market demand.
Net profit margin improved to 20%, reflecting effective cost management strategies.
Expansion into new product lines contributed significantly to overall sales.

NEGATIVES

Operating expenses rose 10%, impacting overall profitability despite revenue growth.
Increased competition in the sector has led to pricing pressures on key products.
Supply chain disruptions caused delays in product launches, affecting market share.

Quarterly Results Data

Field	Trend	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25
Revenue		2,578.62	2,708.10	2,606.96	2,441.10	2,893.42	3,076.51	3,230	3,570.35
Expenses		2,017.50	2,130.56	2,119.37	1,964.07	2,330.31	2,339.19	2,813.43	3,112.91
Operating Profit		561.12	577.54	487.59	477.03	563.11	737.32	416.57	457.44
Other Income		58.62	59.98	70.13	92.13	100.60	109.43	77.32	79.88
Interest		6.34	8.62	9.18	9.38	10.91	7.10	220.93	170.65
Depreciation		87.35	96.48	109.73	104.69	107.74	105.62	192.30	218.68
Profit Before Tax		624.47	640.99	562.33	571.58	667.62	849.32	497.33	540.49
Tax		130.28	129.81	102.52	94.98	124.55	190.44	112.81	95.87
Net Profit		494.19	511.18	459.81	476.59	543.07	658.88	384.52	444.62
Eps in Rs		12.15	12.51	11.33	11.76	13.39	16.31	9.45	10.62